Two compounds sit in the PubChem registry one oxygen atom apart. Adrafinil is C15H15NO3S. Modafinil is C15H15NO2S. Structurally the relationship is trivial: adrafinil carries a hydroxamic acid where modafinil carries a plain amide. Historically the relationship is the whole story. The modafinil discovery ran in reverse: nobody set out to make this molecule. It was found by asking what the body did to the compound that came first.
A compound identified in 1974, and a disappointing clinic
Adrafinil was identified by the French pharmaceutical company L. Lafon Ltd in 1974. In animal work it produced a significant, dose-dependent increase in motor activity in mice without the peripheral sympathomimetic effects that defined the stimulants of the era. That last clause is the interesting one. A compound that raises activity while leaving the cardiovascular periphery comparatively untouched does not fit the amphetamine template, and it suggested the mechanism was somewhere else.
The clinic came next and went badly. As early as 1977 to 1978, the French sleep researcher Michel Jouvet prescribed adrafinil to narcoleptic patients. The results were not consistent. In a different company this is where the file closes.
The modafinil discovery: a metabolite that outperformed its parent
What kept it open was pharmacokinetics. Studying the kinetics of adrafinil led to the identification of an active metabolite, and that metabolite was modafinil. In 1983 Jouvet and Bastuji prescribed modafinil itself to patients with narcolepsy and idiopathic hypersomnia, and this time the result was unambiguous: a significant decrease in excessive daytime sleepiness and in sleep attacks in the majority of patients.
This is a recurring pattern in medicinal chemistry rather than a curiosity. When a parent compound is converted in vivo into something more active, the parent is functioning as a prodrug, and the prodrug is frequently the worse product. It adds a conversion step that varies between individuals, it delays onset while the metabolite accumulates, and it generates additional species that have to be tracked analytically. Removing the N-hydroxy group removes that entire layer.
What one oxygen atom actually changes
The N-hydroxy group in adrafinil makes it a hydroxamic acid, a functional group that is markedly more acidic and more polar than the corresponding primary amide. Strip it and you are left with 2-benzhydrylsulfinylacetamide: a neutral amide, lower molecular weight, simpler to characterise.
| Property | Adrafinil | Modafinil |
|---|---|---|
| PubChem CID | 3033226 | 4236 |
| CAS number | 63547-13-7 | 68693-11-8 |
| Development code | CRL-40028 | CRL-40476 |
| Molecular formula | C15H15NO3S | C15H15NO2S |
| Molecular weight | 289.4 | 273.4 |
| IUPAC name | 2-benzhydrylsulfinyl-N-hydroxyacetamide | 2-benzhydrylsulfinylacetamide |
Both molecules keep the feature that makes this chemical series distinctive: a sulfinyl group bridging a benzhydryl (diphenylmethyl) unit and an acetamide. The sulfur is neither a sulfide nor a sulfone but a sulfoxide, sitting at an intermediate oxidation state. That single sulfur atom does more work than the rest of the scaffold, and it carries a consequence that took another two decades to commercialise.
The stereocentre hiding in plain sight
A sulfoxide sulfur bearing two different substituents and a lone pair is a stereocentre. Modafinil therefore exists as two enantiomers, and the compound that was registered and sold is the racemate.
The single enantiomer was later registered separately as armodafinil, the (R)-form, with its own CAS number (112111-43-0) and its own PubChem entry, despite sharing the molecular formula C15H15NO2S and a molecular weight of 273.4 with the racemate. Nothing about the elemental composition distinguishes them. Mass spectrometry cannot separate them. Only a chiral method can.
For anyone running analytical work this is the practical lesson of the whole series: a purity figure from an achiral column says nothing about enantiomeric composition. A sample can be 99.9% pure by reversed-phase HPLC and still be a mixture of two distinct registered substances. Enantiomeric excess is a separate measurement, made on a chiral stationary phase, and it needs its own analytical reference standard to be meaningful.
Related substances: why the family matters in the laboratory
The benzhydrylsulfinyl scaffold tolerates change at two positions, and the registry reflects that. Oxidise the sulfoxide further and you reach the sulfone. Hydrolyse the amide and you reach the carboxylic acid, modafinil acid, registered as C15H14O3S under CAS 63547-24-0. Each of these differs from modafinil by a small, chemically plausible transformation, which is precisely the profile of a potential process impurity or degradation product.
A related-substances method for this series therefore has to resolve compounds that share a chromophore, share most of their mass and differ by 16 daltons or by the amide-to-acid conversion. This is not exotic analytical chemistry, but it is unforgiving work, and it is the reason each member of the family is characterised and sold as a separate reference material rather than treated as a variant of the same thing.
From a reluctant company to a registered medicine
The commercial history is less tidy than the chemistry. L. Lafon Ltd was initially not interested in developing modafinil for market. It was Jouvet’s insistence that moved the company to begin clinical trials in healthy volunteers and in narcoleptic patients alongside animal studies. Those results were strong enough that modafinil was used by the French army during the Gulf War in January and February 1991, and the drug was officially registered in France in 1992. Multicentre controlled trials in North America subsequently confirmed the European findings, and the United States Food and Drug Administration approved labelling for the compound in December 1998.
Twenty-four years separate the identification of adrafinil from that approval, and the molecule that arrived at the end was not the one that started the programme. It was the one the first molecule turned into.
Frequently asked questions
What is the chemical difference between adrafinil and modafinil?
Adrafinil (C15H15NO3S, CAS 63547-13-7) carries an N-hydroxy group on the amide nitrogen, making it a hydroxamic acid. Modafinil (C15H15NO2S, CAS 68693-11-8) has a plain primary amide in the same position. The two structures differ by one oxygen atom and 16 units of molecular weight.
Why was modafinil developed instead of adrafinil?
Modafinil was identified as the active metabolite of adrafinil during kinetic studies. Developing the metabolite directly removes the in vivo conversion step, which otherwise introduces inter-individual variability, delays onset while the active species accumulates, and adds further metabolites that must be characterised.
Is modafinil chiral?
Yes. The sulfoxide sulfur is a stereocentre, so modafinil exists as two enantiomers. The originally registered substance is the racemate. The single (R)-enantiomer, armodafinil, holds a separate CAS number (112111-43-0) despite having an identical molecular formula and molecular weight.
Can standard HPLC confirm enantiomeric purity?
No. Enantiomers have identical mass and identical behaviour on achiral stationary phases, so reversed-phase HPLC and mass spectrometry cannot distinguish them. Determining enantiomeric excess requires a chiral stationary phase and a reference standard of known configuration.
References
- Billiard M, Broughton R. Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions. Sleep Medicine 2018;49:69-72.
- PubChem Compound Summary CID 4236, Modafinil. National Center for Biotechnology Information.
- PubChem Compound Summary CID 3033226, Adrafinil. National Center for Biotechnology Information.
- PubChem Compound Summary CID 9690109, Armodafinil. National Center for Biotechnology Information.
- PubChem Compound Summary CID 3085267, Modafinil acid. National Center for Biotechnology Information.
- PROVIGIL (modafinil) Tablets, FDA approved labeling, December 1998. US Food and Drug Administration.
Research use only. Nonsensia Lab supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.
Filed under: Chemistry & Discovery
This article is part of our guide to Where Research Compounds Come From: Discovery, Synthesis and Structure.
The compound discussed in this article is available as an analytical reference standard: Modafinil ≥99.5% HPLC – Analytical Reference Standard | CAS 68693-11-8.